IgA Nephropathy Secondary to Ipilimumab Use

Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sean C. Dougherty, Nisa Desai, Helen P. Cathro, Amanda Renaghan
Formato: article
Lenguaje:EN
Publicado: Karger Publishers 2021
Materias:
Acceso en línea:https://doaj.org/article/c509c83f285d4cb4aa1d2601709d1b42
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!